Published in Gene Therapy Weekly, May 24th, 2001
To improve cytotoxicity while reducing concentrations of GCV to therapeutic levels, C. Liu and colleagues took advantage of the herpes simplex virus-1 structural protein, VP22, and its ability to improve cellular trafficking.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.